NovoCure (NVCR) Share-based Compensation Growth (1y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 9.69% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 3.57% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -4.08% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 12.16% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 12.94% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 26.61% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 59.09% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 31.63% |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | 113.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 113.21% |
| Dec 31, 2025 | -68.42% |
| Sep 30, 2025 | -6.51% |
| Jun 30, 2025 | -17.87% |
| Mar 31, 2025 | -13.30% |
| Dec 31, 2024 | 259.89% |
| Sep 30, 2024 | 19.05% |
| Jun 30, 2024 | -2.78% |
| Mar 31, 2024 | -12.79% |
| Dec 31, 2023 | -41.45% |
| Sep 30, 2023 | 0.16% |
| Jun 30, 2023 | 26.79% |
| Mar 31, 2023 | 56.06% |
| Dec 31, 2022 | 32.97% |
| Sep 30, 2022 | 2.12% |
| Jun 30, 2022 | -7.38% |
| Mar 31, 2022 | 32.77% |
| Dec 31, 2021 | 10.48% |
| Sep 30, 2021 | 28.02% |
| Jun 30, 2021 | 48.54% |
| Mar 31, 2021 | 13.93% |
| Dec 31, 2020 | 37.94% |
| Sep 30, 2020 | 40.33% |
| Jun 30, 2020 | 36.69% |
| Mar 31, 2020 | 71.59% |
| Dec 31, 2019 | 38.12% |
| Sep 30, 2019 | 36.83% |
| Jun 30, 2019 | 34.55% |
| Mar 31, 2019 | 13.25% |
| Dec 31, 2018 | 67.42% |
| Sep 30, 2018 | 21.44% |
| Jun 30, 2018 | 34.82% |
| Mar 31, 2018 | 86.80% |
| Dec 31, 2017 | 34.60% |
| Sep 30, 2017 | 53.38% |
| Jun 30, 2017 | 34.29% |
| Mar 31, 2017 | -16.40% |
| Dec 31, 2016 | 5.21% |
| Sep 30, 2016 | 92.14% |
| Jun 30, 2016 | 114.17% |
| Mar 31, 2016 | 201.10% |
| Dec 31, 2015 | 253.39% |
| Sep 30, 2015 | 142.99% |